The Federal Antimonopoly Service has agreed on the cost of a new drug from Promomed

The Federal Antimonopoly Service has registered prices for all five therapeutic dosages of Velgia^® - from 4279.55 rubles to 10270.92 rubles, depending on the dosage.

Velgia® continues the Promomed product line aimed at overweight, obese, and type 2 diabetic patients. Earlier, the Company launched the blockbuster drug Quincenta^® (an analogue of the acclaimed Ozempika), intended for the treatment of diabetes mellitus.

Promomed produces the drug within the framework of the full cycle concept: from the substance to the finished dosage form. The drug is expected to be put into commercial circulation in the near future, Velgia^® will be available for purchase as early as the 4th quarter of 2024.

Velgia^® Promomed has been developed for the treatment of obesity, it contains specially selected concentrations and increased dosages of the active substance, which increases its effectiveness. The drug significantly reduces weight and helps to correct metabolic disorders that underlie the formation of a number of cardiovascular and oncological diseases.

Semaglutide, the main active ingredient of the new drug Velgia^®, has a positive effect on most organs and systems. One drug, which should be taken only once a week, gives many positive effects. In fact, this is a modern and scientifically proven anti-aging therapy that prolongs an active life and allows you to make the "medicine of the future" a real present.

Ilya Bardin-Denisov, General Director of Promomed DM LLC: "We continue to strictly follow the strategy of developing and releasing new drugs in the most promising segments of the pharmaceutical market. The creation and release of Velgia^® confirms Promomed's leadership in the segment of obesity and diabetes treatment. Registration of the price of the drug by the regulatory authorities brings another step closer to affordable weight loss therapy."